I. Project Name: Beihu Northeast Changchun Biological Vaccine Industrial Park

II. Project Location: Beihu Sci-Tech Industry Development Zone of Changchun New Area

III. Industrial Categorization: Service Industry

IV. Project Profile and Construction Content

The project is planned to get situated inside the Beihu Sci-Tech Industry Development Zone, Changchun New Area, covering a land area of two square kilometers. It is to be planned and constructed in accordance with the industrial pattern of “one institute, two bases and one center”, namely, Headquarters of National Research Institute for Biological Products, Human Biological Vaccine Industrial Base, Animal Vaccine Industrial Base and Biological Product Technology Research and Development Incubation Center. Upon completion, it will bring about an output value of RMB20 billion and a total tax and profit of RMB500 million.

V. Analysis of Market Prospect

According to the Planning on the Construction of Vaccine Supply System launched by the State Council, vaccine supply system will be further improved up to the level of developed countries in terms of dealing with emergencies and major epidemics by 2020. In the future, with the improvement of innovation capacities of a number of enterprises and a batch of innovative varieties to be put in market, and facilitated by policy promotion, and expansion of investment and immunity planned by governments, the huge population and potential demand are expected to promote once again the rapid development of vaccine industry. Compared with developed countries, however, the domestic vaccine market is still in the initial stage of development. The vaccines produced at home are mainly imitated, and the development of new medicines is still slow. Most vaccines applied for registration at home are traditional vaccines. The innovative development capacity of new vaccines including tuberculosis vaccine, pneumonia combined vaccine and rotavirus vaccine is still insufficient. The park will play a greater role in driving the industrial competitiveness of the region up to a new level.

VI. Investment Scale: RMB10 billion to be invested in total.

VII. Cooperation Mode: 1. Global 500 biological vaccine manufacturers. 2. China’s top 500 vaccine manufacturers. 3. Listed biological vaccine companies; 4. Famous biological vaccine enterprises at home in search for partners to jointly invest and cooperate in the construction of infrastructure and development of open space in the park.

VIII. Contact: The Bureau of Commercial and Foreign Affairs, Changchun New Area, 0431-81335588.